1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Intra-Cellular Poised To Add MDD To Caplyta’s Label

Second Phase III Is Positive

 
• By Joseph Haas

Caplyta succeeded in a second Phase III study as adjunctive therapy for major depression, putting the schizophrenia/bipolar disorder drug on track for sNDA filing later in 2024.

Intra-Cellular will file lumateperone for approval in adjunctive MDD

With a second successful Phase III readout in major depressive disorder this quarter for Caplyta (lumateperone), Intra-Cellular Therapies, Inc. said on 18 June that it intends to seek what would be the drug’s third indication this year, and anticipates approval in the second half of 2025. While Caplyta works toward blockbuster status as a therapy for schizophrenia and bipolar I/II disorder, analysts said an MDD indication should add billions more to its revenue potential.

Key Takeaways

  • Intra-Cellular followed April’s successful Phase III trial of Caplyta in depression with a second trial virtually replicating those results.

CEO Sharon Mates told a same-day call that Intra-Cellular will file a supplemental new drug application with the US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 
• By Sushmita Panda

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Replimune CRL Could Hold Warning For Accelerated Approvals

 
• By Jessica Merrill

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

More from R&D

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 
• By Jessica Merrill

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.